Skip to content

Maudsley Model of Anorexia Nervosa Treatment for Adolescents and Young Adults (MANTR-a)

MANTR-a: Evaluation of a Therapeutic Intervention for Adolescents and Young Adults With Anorexia Nervosa

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03535714
Enrollment
100
Registered
2018-05-24
Start date
2018-04-25
Completion date
2022-08-31
Last updated
2021-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia, Anorexia Nervosa

Keywords

Treatment, Psychotherapy, Young Adult, Adolescence

Brief summary

The aim of this study is to test effectiveness of a new treatment program for adolescents and young adults within the age of 14-21 suffering from AN (MANTR-a) compared to treatment as usual (TAU).

Detailed description

Anorexia nervosa (AN) is a serious mental illness which leads untreated to aggravation of symptomatology and chronification. Among all mental illnesses, AN has the highest mortality rate, which is about 5.1 per 1000 people per year. High drop-out rates (up to 40%) or small treatment motivation constrains treatment success. Since the onset of AN is mainly in adolescence, it is important to start with therapy as early as possible and establish an effective single-setting treatment program for this age group to prevent chronification. MANTR-a (Maudsley model of anorexia nervosa treatment for adolescents) is an innovative, theory-based, tailored treatment program which combines a cognitive behavioural approach with motivational interviewing. The main focus of the treatment program is the transformation maintaining factors of AN, like personality aspects, pro-anorexic beliefs, emotion regulation strategies, thinking styles and obstructive behaviour from caregivers. The aim of this study is the examination ot the effectiveness of the MANTR-a treatment program for adolescents and young adults. Therefore we compare MANTR-a (intervention group) with treatment as usual (control group). Assessments will be conducted before treatment (T0, baseline), after six months (T1), after 12 months (T2) and after 18 months (T3, follow-up) via questionnaires, interviews and neuropsychological measurements. Process evaluation takes place after every session. Each group consists of female adolescents and young adults within the age of 14-21 suffering from AN (ICD-10: F50.0, F50.1), resulting in an overall sample size of 100. The long-term goal of the study is to provide an evidence-based outpatient treatment for children and adolescents with AN in order to prevent a chronic course of the disease.

Interventions

BEHAVIORALMANTR-a treatment

MANTR-a treatment

Sponsors

Pharmig - Gesundheitsziele aus dem Rahmen-Pharmavertrag
CollaboratorOTHER
Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
14 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* ICD-10 diagnosis of anorexia nervosa (F50.0) or atypical anorexia nervosa (F50.1).

Exclusion criteria

* life-threatening AN requiring immediate inpatient treatment as defined by NICE (2017) * insufficient cognitive ability * insufficient knowledge of German language to understand the treatment * severe mental or physical illness that needs treatment on its own (e.g. psychosis) * substance abuse * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Increase of BMI12 monthsWeight and height will be assessed and combined to report BMI in kg/m\^2
Improvement of eating disorder symptomatology based on professional's rating12 monthsProfessionals use a structured clinical interview (Eating Disorder Examination - EDE) to rate severity of eating disorder symptomatology
Improvement of eating disorder symptomatology based on patient's self-rating12 monthsEating Disorder Inventory-2 (EDI-2) is used to assess eating disorder symptomatology from a patients's view

Secondary

MeasureTime frameDescription
Group differences: increase of BMI6 months, 12 months, 18 monthsGroup differences are calculated based on BMI (weight and height will be assessed and combined to report BMI in kg/m\^2)
Group differences: improvement of eating disorder symptomatology based on professional's rating6 months, 12 months, 18 monthsGroup differences are calculated based on professional's rating in a structured clinical interview (Eating Disorder Examination - EDE)
Group differences: improvement of eating disorder symptomatology based on patient's self-rating6 months, 12 months, 18 monthsGroup differences are calculated based on a patient's self-rating questionnaire (Eating Disorder Inventory-2)
Improvement of comorbid symptomatology based on professional's rating6 months, 12 months, 18 monthsProfessionals use a structured clinical interview (Diagnostisches Interview bei psychischen Störungen im Kindes- und Jugendalter) to rate severity of comorbid symptomatology
Reduction of anxiety6 months, 12 months, 18 monthsState-Trait-Angstinventar (STAI X1, STAI X2) is used to assess severity of anxiety from a patients's view
Reduction of depression6 months, 12 months, 18 monthsBeck Depressionsinventar (BDI-II) is used to assess severity of depression from a patients's view
Reduction of obsessive-compulsive symptomatology6 months, 12 months, 18 monthsZwangsinventar (OCI-R) is used to assess severity of obsessive-compulsive symptomatology from a patients's view
Increase of BMI6 months, 18 monthsWeight and height will be assessed and combined to report BMI in kg/m\^2
Increase of central coherence12 monthsCentral coherence is measured with Rey-Osterrieth Complex Figure Test (ROCF)
Increase of emotion recognition12 monthsEmotion recognition is measured with Frankfurter Program to test and to teach the recognition of facial affect (FEFA-2)
Influence of motivation of change12 monthsMotivation of change is measured with Anorexia nervosa Stages of Change Questionnaire (ANSOCQ)
Quality of life (group differences, improvement over time)6 months, 12 months, 18 monthsQuality of Life is measured with Lebensqualität von Kindern und Jugendlichen (ILK)
Influence of therapeutic relationship6 months, 12 monthsTherapeutic relationship is measured with Fragebogen zur therapeutischen Beziehung für Kinder und Jugendliche (FTB-KJ)
Influence of treatment contentment6 months, 12 monthsTreatment contentment is measured with Fragebogen zur Beurteilung der Behandlung (FBB)
Changes in personality12 monthsChanges in personality are measured with Junior Temperament und Charakter Inventar (JTCI 12-18R)
Increase of cognitive flexibility12 monthsCognitive flexibility is measured with Computergestütztes Kartensortierverfahren (CKV)
Improvement of eating disorder symptomatology based on professional's rating6 months, 18 monthsProfessionals use a structured clinical interview (Eating Disorder Examination - EDE) to rate severity of eating disorder symptomatology
Improvement of eating disorder symptomatology based on patient's self-rating6 months, 18 monthsEating Disorder Inventory-2 (EDI-2) is used to assess eating disorder symptomatology from a patients's view

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026